Health and Healthcare

2020 IPO Next-Gen Cancer Screening AnPac Sees Growth in US and China

xavierarnau / E+ via Getty Images

The announcement that AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) has entered into a three-year strategic cancer screening collaboration contract with Beijing Yuan Jian Health Management in China lit a fire under the shares Friday morning.

In terms of the specifics, this contract contains a minimum of 76,000 paid cancer screening tests, including at least 6,000 paid tests in 2020, 25,000 paid tests in 2021 and 45,000 paid tests in 2022.

The total value of the contract is valued just over $3 million and exceeds the previous contract by more than double the number of paid tests per year. Note that the company currently has a market cap of $90 million.

Looking ahead, AnPac Bio is pushing ahead with its commercialization plan of CDA cancer screening tests in the United States, with ongoing commercialization efforts at its San Jose lab and the opening of its second lab at Philadelphia.

Beijing Yuan Jian Health Management is a Chinese health management firm. It has collaborated with various academic and medical institutions, including universities, hospitals and other health care organizations in China and the United States.

AnPac is a biotechnology company focused on early cancer screening and detection. It has 121 issued patents, two certified clinical laboratories in China and one CLIA and CAP-accredited clinical laboratory in the United States.

AnPac Bio-Medical Science stock traded up about 18% Friday morning, at $8.05 in a 52-week range of $5.22 to $12.18. The consensus price target is $18.00.

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s made it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

  1. Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
  2. Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
  3. Choose Your  Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!

 

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.